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In hemolytic diseases, such as sickle cell disease (SCD), intravascular hemolysis results in
the release of hemoglobin, heme, and heme-loaded membrane microvesicles in the
bloodstream. Intravascular hemolysis is thus associated with inflammation and organ injury.
Complement system can be activated by heme in vitro. We investigated the mechanisms by
which hemolysis and red blood cell (RBC) degradation products trigger complement
activation in vivo. In kidney biopsies of SCD nephropathy patients and a mouse model with
SCD, we detected tissue deposits of complement C3 and C5b-9. Moreover, drug-induced
intravascular hemolysis or injection of heme or hemoglobin in mice triggered C3 deposition,
primarily in kidneys. Renal injury markers (Kim-1, NGAL) were attenuated in C3–/–
hemolytic mice. RBC degradation products, such as heme-loaded microvesicles and heme,
induced alternative and terminal complement pathway activation in sera and on endothelial
surfaces, in contrast to hemoglobin. Heme triggered rapid P selectin, C3aR, and C5aR
expression and downregulated CD46 on endothelial cells. Importantly, complement
deposition was attenuated in vivo and in vitro by heme scavenger hemopexin. In
conclusion, we demonstrate that intravascular hemolysis triggers complement activation in
vivo, encouraging further studies on its role in SCD nephropathy. Conversely, heme
inhibition using hemopexin may provide a novel therapeutic opportunity to limit complement
activation in hemolytic diseases.
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Introduction
Intravascular hemolysis is a pathological event, leading to red blood cell (RBC) degradation and liberation 
of  hemoglobin (Hb) in the bloodstream. Upon depletion of  the Hb-scavenging protein haptoglobin (Hp), 
Hb oxidation occurs and heme is released from the globin chains and is rapidly bound by hemopexin (Hx) 
(1). Upon Hx saturation, the remaining labile cell–free and Hx-free heme mediates oxidative stress, vascu-
lar damage, and inflammation (2).
Heme has been described as a key player in the pathogenesis of  various diseases, such as malaria, sep-
sis, transfusion complications, and sickle cell disease (SCD) (2). SCD is a severe genetic disease and a major 
In hemolytic diseases, such as sickle cell disease (SCD), intravascular hemolysis results in the 
release of hemoglobin, heme, and heme-loaded membrane microvesicles in the bloodstream. 
Intravascular hemolysis is thus associated with inflammation and organ injury. Complement 
system can be activated by heme in vitro. We investigated the mechanisms by which hemolysis 
and red blood cell (RBC) degradation products trigger complement activation in vivo. In kidney 
biopsies of SCD nephropathy patients and a mouse model with SCD, we detected tissue deposits of 
complement C3 and C5b-9. Moreover, drug-induced intravascular hemolysis or injection of heme 
or hemoglobin in mice triggered C3 deposition, primarily in kidneys. Renal injury markers (Kim-1, 
NGAL) were attenuated in C3–/– hemolytic mice. RBC degradation products, such as heme-loaded 
microvesicles and heme, induced alternative and terminal complement pathway activation in sera 
and on endothelial surfaces, in contrast to hemoglobin. Heme triggered rapid P selectin, C3aR, 
and C5aR expression and downregulated CD46 on endothelial cells. Importantly, complement 
deposition was attenuated in vivo and in vitro by heme scavenger hemopexin. In conclusion, we 
demonstrate that intravascular hemolysis triggers complement activation in vivo, encouraging 
further studies on its role in SCD nephropathy. Conversely, heme inhibition using hemopexin may 
provide a novel therapeutic opportunity to limit complement activation in hemolytic diseases.
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public health concern in many countries, affecting around 6 million individuals on all inhabited continents 
(3). In SCD heme participates in vaso-occlusive crises (VOC), endothelial cell (EC) toxicity, and ROS gen-
eration (4–6). SCD patients display high levels of  heme-loaded RBC microvesicles (MVs), which distribute 
heme to tissues and contribute to EC damage and VOCs (5, 7). Heme acts as a damage-associated molecu-
lar pattern and triggers activation of  monocytes (8) and ECs (4–6). In vitro studies suggest that heme acti-
vates the innate immune complement system in sera and on RBC surfaces (2, 9–12). In addition, triggering 
complement by heme causes an inflammatory reaction, leading to the release of  anaphylatoxins C3a and 
C5a and the formation of  the membrane attack complex C5b-9 on EC surfaces (12). Clinical observations 
showed a significant increase of  pathological markers of  complement activation in SCD sera, especially 
during painful VOCs (13–15), as well as increased levels of  surface-bound C3 fragments on RBC (13, 16).
Renal damage is a complication of  intravascular hemolysis in many diseases, including SCD (3). More-
over, the kidney is particularly susceptible to complement attack (9). In SCD nephropathy, the exact mech-
anism and pathophysiological relevance of  complement activation is not established, despite some early 
reports mentioning C3 fragment deposition in kidneys in humans and in a mouse model of  SCD (17–19).
Here, we demonstrate that complement activation proceeds all the way through the terminal pathway 
during SCD nephropathy in humans as well as in kidneys of  two SCD mouse models. Moreover, hemoly-
sis-related products — Hb-derived heme and heme-loaded RBC-derived MVs — activated complement in 
vitro, in sera and on cultured ECs, as well as in vivo, in a mouse model of  intravascular hemolysis. In vivo 
and in vitro, the deposition of  the C3 fragments was antagonized by pretreatment with Hx.
Results
Cohort of  SCD nephropathy. On light microscopy, the predominant pattern of  the observed glomerular 
disease was specific SCD glomerulopathy (n = 5), focal segmental glomerulosclerosis (n = 3), mem-
branoproliferative glomerulonephritis (n = 3), and thrombotic microangiopathy (TMA) (n = 2) (Table 
1). In 10 of  13 patients, glomerular lesions were associated with chronic tubulointerstitial lesions with 
different degrees of  interstitial fibrosis and tubular atrophy. Three patients had tubular casts and six 
patients showed inflammatory cell infiltrate (macrophages). Perls’ staining revealed hemosiderosis near 
or in renal tubules in 7 of  8 tested patients. Chronic vascular lesions were observed in 10 of  13 patients, 
resulting in hyaline arteriosclerosis in most of  patients. One patient had TMA lesions involving extraglo-
merular small vessels. By immunofluorescence, C3 staining was positive in 9 of  11 patients in glomeruli 
(capillary walls and/or mesangium) and/or in vessels. Polyclonal immunoglobulin staining was positive 
in glomeruli of  4 of  10 patients.
Complement deposition is present in kidneys of  patients and mice with SCD. C3 staining was positive in 9 of  
11 (82%) SCD nephropathy patient biopsies in glomeruli (capillary walls and/or mesangium) and/or ves-
sels (Figure 1A and Table 1) and was absent from normal kidneys. Most (2 of  3) tested SCD biopsies were 
positive for C9 staining (Figure 1B). A graft rejection biopsy is shown as positive control for C3 and C9 
staining. Polyclonal immunoglobulin staining was positive in glomeruli of  5 of  11 (45%) patients (Table 1).
A similar pattern of  increased C3 and C5b-9 deposition was detected in transgenic HbSS (Figure 1C) 
as well as SAD mouse kidneys (Figure 1D) compared with HbAA and WT control littermates, respec-
tively. C3 and C5b-9 deposition was mostly intraglomerular and partly peritubular (Figure 1, C and D). 
Moreover, complement activation partially colocalized with EC marker CD31 in glomeruli (Figure 1E). 
Both SAD and HbSS mice were characterized by increased plasma levels of  RBC MVs and cell-free heme 
(Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.96910DS1).
Description of  a model of  intravascular hemolysis. SCD nephropathy, where we detected C3 deposits (Fig-
ure 1A), is a chronic disease. We used a well-characterized model of  drug-induced intravascular hemolysis 
in mice (9, 10) in order to determine whether the complement deposits observed in the kidneys of  sickle 
patients and sickle mice were directly related to hemolysis.
Widespread hemolysis was evident in mice treated with phenylhydrazine (PHZ) from the darker color 
of  the urine and organs (data not shown), markedly decreased hematocrits, increased cell-free plasma Hb, 
and RBC MV and heme levels at 24 hours after injection (Supplemental Figure 2, A–D). Intravascular 
hemolysis was already evident 6 hours after injection (Supplemental Figure 2D). About 15% of  the total 
plasma heme was contained in the MVs, as measured by the decrease in the absorbance of  plasma before 
and after ultracentrifugation to remove the MVs (Supplemental Figure 2E). The plasma concentration of  
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endogenous Hx was about 0.15 mg/ml in resting mice. Six hours after PHZ injection, Hx levels were sub-
stantially decreased, but they increased again 24 hours after treatment, suggesting consumption by hemo-
lysis followed by de novo expression (Supplemental Figure 2F). Conversely, treatment with exogenous 
human sequence Hx did not modulate endogenous mouse Hx levels in plasma (Supplemental Figure 2F). 
Human Hx was found at concentrations of  up to 0.4 mg/ml (over 2-fold above basal levels of  endogenous 
Hx) 6 hours after Hx injection and remained detectable for at least 24 hours (Supplemental Figure 2G).
Immunohistochemistry of  kidney sections revealed no HO-1 expression in PBS- and Hx-treated 
mice (Supplemental Figure 3A). Pharmacological induction of  hemolysis with PHZ triggered HO-1 
expression within 24 hours. This was not modified by Hx supplementation (Supplemental Figure 3A). 
Perls’ Prussian blue staining for hemosiderin, a hallmark of  hemolysis, became evident 24 hours after 
PHZ injection (Supplemental Figure 3B). The analysis of  kidney sections from PBS- and PHZ-treated 
WT mice revealed no gross modification of  histology (hematoxylin and eosin staining) and glomerulus 
size by light microscopy (Supplemental Figure 3, C and D).
Intravascular hemolysis induced heme-dependent complement deposits in kidneys and on endothelium and 
complement-mediated renal injury. We detected a significant increase in C3 activation fragment deposi-
tion in renal glomeruli within 6 hours (Figure 2A) after inducing intravascular hemolysis with PHZ; 
this increase was maintained for at least 24 hours (Figure 2B). This was indeed concomitant with 
Table 1. Description of the renal biopsies of patients with SCD nephropathy
Patient no. 1 2 3 4 5 6 7 8 9 10 11 12 13
Light microscopy
No. glomeruli 17 15 15 25 na 18 7 22 22 9 12 10 36
No. sclerotic glomeruli 
(%)
0 (0) 5 (33) 10 (66) 8 (32) na 4 (22) 3 (43) 5 (23) 6 (27) 2 (22) 3 (25) 1 (10) 6 (17)
Glomerular lesions
Glomerular 
hypertrophy
++ ++ + ++ +++ + + - na ++ ++ ++ +
Mesangial 
hypertrophy
+ ++ + ++ - ++ +++ - ++ ++ ++ + +
Mesangial 
proliferation
- ++ + - + - - - - - - -
Duplication of GBM - ++ - ++ + +++ + ++ - + + - -
FSGS - - ++ - + + + + ++ - + + ++
Capillaries distention + na - - + + - - - + ++ ++ na
Intracapillary 
thrombus
- - - - - + - - - + - + +
Tubulointerstitial 
lesions
Interstitial fibrosis - +++ +++ +++ - +++ - +++ ++ + +++ ++ +++
Tubular atrophy - +++ ++ +++ - +++ - +++ ++ + +++ ++ +++
Cellular infiltration - - - - - - - + + + + + +++
Casts - + + - - - - - - - + - na
Vascular lesions HA HA HA HA NS NS, HA HA NS, HA HA TMA - - NS
Perls’ staining na + na na + na - na + + + + +
Immunofluorescence 
C3 na CW, Mes Mes Vessel - na Mes Vessel Mes CW, 
vessel
Mes, CW - Mes
Fibrin na - - CW - na - - - - - - -
Ig na CW Mes CW - na CW - Mes - - - -
Predominant 
histological pattern
SCDG MPGN FSGS SCDG SCDG MPGN MPGN TMA FSGS TMA SCDG SCDG FSGS
CW, capillary wall; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; HA, hyaline arteriosclerosis; MPGN, 
membranoproliferative glomerulonephritis, Mes, mesangium; na, not available; NS, nephrosclerosis; SCDG, sickle cell disease glomerulopathy; TMA, 
thrombotic microangiopathy lesions. Lesions were graded using the following scale: -, no lesion; +, rare or few lesions; ++, moderate lesions; and +++, 
severe lesions.
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intravascular hemolysis (Supplemental Figure 2D). C3b/iC3b-positive staining was observed in glom-
eruli or around blood vessels and tubules within kidney sections of  PHZ-treated mice, located in a 
similar fashion to SCD mice. The staining was specific, since it was completely absent from PBS- or 
PHZ-injected C3–/– mice (Supplemental Figure 4). C3 deposits in glomeruli partially colocalized with 
EC marker vWF (Figure 2B). A similar pattern of  complement activation was reproduced in the heart, 
Figure 1. Patients suffering from SCD nephropathy and SCD mice have complement deposition within kidneys. (A) C3 fragment staining (false 
color green) and (B) C9 staining (brown) of kidney biopsies of patients with SCD nephropathy, performed by immunofluorescence of frozen tissue and 
immunohistochemistry of paraffin-embedded tissues, respectively. A normal protocol kidney allograft biopsy performed at 3 months was used as a 
negative control and a biopsy of a patient with acute humoral rejection was used as a positive control for the staining. (C) C3b/iC3b (false color green) 
and C5b-9 (false color red) staining of kidney sections of HbAA and HbSS mice. Quantification of the C3 and C5b-9 staining in HbSS (n ≥ 7 mice per 
group) and HbAA (n ≥ 4 mice per group) mouse kidney glomeruli. (D) C3b/iC3b (false color green) and C5b-9 (false color red) staining of kidney sections 
of SAD mice and WT littermates. Quantification of the C3 and C5b-9 staining in kidney glomeruli (n ≥ 7 mice per group). (E) Double staining of SAD and 
HbSS mouse kidney sections for C3b/iC3b (false color green) and endothelial marker CD31 (false color red). The merge image indicates colocalization 
in orange. One glomerulus was focused on. *P < 0.05; **P < 0.005; ***P < 0.001, Mann-Whitney test. Values are shown as box plots with median and 
minimum/maximum points. Scale bar: 50 μm. Original magnification, ×26.
5insight.jci.org   https://doi.org/10.1172/jci.insight.96910
R E S E A R C H  A R T I C L E
Figure 2. Hemolysis induced heme-dependent complement deposition in kidney in vivo. (A) C3b/iC3b (false green color) staining of frozen kidney sections 
of mice injected with PBS or PHZ and sacrificed at 6 hours. Quantification of C3 fragment staining in glomeruli (n ≥ 5 mice per group). (B) Double staining of 
PHZ-injected mouse kidney sections for C3b/iC3b (false color green) and endothelial marker vWF (false color red). The merge image indicates colocalization 
(white arrows) in orange. (C–E) Evaluation of the renal injury in WT and C3–/– mice (n = between 4 and 12 mice per group) injected with PBS or PHZ by analyzing 
gene expression by RTqPCR. (C) NGAL. (D) Kim-1. (E) HO-1. (F) Comparison of the quantification of the C3 fragment staining in glomeruli of mice injected with 
PBS, PHZ, heme, or hemoglobin (Hb) (n ≥ 10 mice per group). (G) C3b/iC3b (false green color) staining and quantification in glomeruli of frozen kidney sections 
of mice injected with PBS or PHZ, with or without hemopexin (Hx) at 24 hours after treatment. (H) C3b/iC3b (false green color) staining and quantification in 
glomeruli of frozen kidney sections of mice injected with PBS or PHZ, with or without haptoglobin (Hp) at 24 hours after treatment (n ≥ 4 mice per group). (I and 
J) C3b/iC3b staining (false color green) of kidney sections of mice injected with heme (I) or Hb (J), with or without Hx. Quantification of C3 staining in glomeruli 
(n ≥ 4 mice per group). * P < 0.05, ** P < 0.005, Mann-Whitney test (A, I, and J); Kruskal-Wallis with Dunn’s test for multiple pairwise comparisons (F–H); 2-way 
ANOVA with Tukey’s test for multiple comparisons (C–E). Values are shown as box plots with median and minimum/maximum points. Scale bar: 50 μm.
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although with a lower apparent C3-staining density (Supplemental Figure 5). C5b-9 staining was neg-
ative (data not shown). Staining for C3b/iC3b revealed that intact RBCs of  PBS-, PHZ-, or heme- 
injected mice remained largely negative (data not shown).
PHZ-treated mice presented with increased renal gene expression of  NGAL and Kim-1, which are 
early and sensitive markers for renal injury (Figure 2, C and D). The expression of  these genes was signifi-
cantly decreased in C3–/– mice, suggesting dependence on complement. In contrast, the gene expression of  
the cytoprotective gene HO-1 was equally upregulated by PHZ in WT and C3–/– mice (Figure 2E).
To find out whether complement deposits in PHZ-treated mice are heme dependent or occur due to 
upstream products (such as Hb), WT mice were injected with hemin and purified human Hb, which also 
resulted in significant C3 deposits (Figure 2F). In addition, scavengers of  heme (human plasma-derived 
Hx, Figure 2G, confirmed as reaching the circulation, Supplemental Figure 2F) or Hb (human plasma-de-
rived Hp, Figure 2H) were used. They both attenuated significantly and nearly completely the comple-
ment activation in kidneys of  PHZ-injected mice. Interestingly, pretreatment with Hx prevented not only 
the complement deposits triggered by hemin (Figure 2I) but also by Hb (Figure 2J), showing that Hb acts 
via release of  heme.
Heme triggers rapid EC surface complement deposition in vitro, which is counteracted by Hx and to a lesser extend 
by human serum albumin. The protective effect of  Hx against complement deposition on ECs in vivo and in 
vitro could be related at least to two phenomena acting against targets in serum and on EC. We compared 
the efficacy of  human serum albumin (HSA) and Hx in in vitro experiments using human umbilical vein 
endothelial cells (HUVECs). Two settings were used. First, heme was added with the serum-free culture 
medium, and after 30 minutes normal human serum (NHS) was added to the wells, while heme was still 
present (H+NHS condition). This condition evaluates the cumulative effect of  the EC activation, which 
renders the cells susceptible to complement deposition, together with the direct activation of  complement 
in serum. In the second setting, ECs were incubated with heme for 30 minutes, and after that the heme-con-
taining supernatant (SN) was removed before addition of  NHS (SN removed condition). This condition 
evaluates the complement activation due to modification of  the EC surface only.
Hemin, but not Hb, activated complement in fluid phase in sera and on the EC surface (Figure 3, A 
and B). We observed that 5 μM Hx inhibited the effects of  up to 50 μM hemin on C3 and C5b-9 deposition, 
while HSA had no effect at this dose and was overall 8- to 10-fold less efficient compared with Hx (Figure 
3, C–F, and Supplemental Figure 6, A–E).
The inhibitory effect of different concentrations of Hx was compared with HSA, because of the high HSA 
concentrations in blood and its affinity, albeit low, for heme (Supplemental Figure 6, A–C). Exposure of ECs 
to heme with increased concentration of Hx prevented dose-dependent C3 fragment deposition on cell surface. 
Around 90% of the inhibition of the deposition caused by 50 μM heme was obtained up to 10 μM Hx in both 
conditions — when SN was removed and when NHS was directly added to media in presence of heme (Sup-
plemental Figure 6A). However, higher amounts of HSA were needed to inhibit C3 fragment deposition, since 
40% of C3 fragment deposition remained detectable with 80 μM HSA (Supplemental Figure 6A). Efficiency 
of HSA was similar when SN was removed or not, as measured by HSA titration (Supplemental Figure 6, B 
and C). However, Hx was more efficient at low doses (≤5 μM) when SN was removed. In order to compare the 
potential inhibitory effect of 5 μM Hx with HSA, HUVECs were treated with 5 μM HSA with increased con-
centration of heme. SN was removed before addition of NHS. C3 fragment deposition and C5b-9 formation 
were not controlled by the addition of 5 μM HSA in the media (Supplemental Figure 6, D and E).
As previously observed by others (4, 20), our experiments in vitro showed that we did not observe 
a one-to-one neutralizing effect between Hx and hemin. This can be explained by the poor solubility of  
hemin, which tends to aggregate in aqueous solutions, decreasing its active concentration (1, 2).
Hx protects the ECs from acquiring a complement-activating phenotype. So far we have seen that the complement 
deposition resulting from PHZ-induced hemolysis was heme dependent and responded to Hx. We therefore 
aimed to study this phenomenon in vitro in a rapid time frame (30 minutes) and to compare the effect of  
hemin and Hb as well as the scavenging by Hx and HSA. On the EC surface, hemin caused a dose-dependent 
decrease of  C3b regulator MCP expression (up to 50%), which was prevented by Hx (Figure 4, A and B). In 
contrast, equimolar HSA had no effect (Supplemental Figure 6F). Moreover, hemin induced rapid, Hx-sensi-
tive expression of  P selectin, a molecule known to recruit C3b on EC surfaces (Figure 4C).
We detected a 2- to 2.5-fold increase in cells with high expression of  anaphylatoxin receptors C3aR 
and C5aR, within 30 minutes, at 50 μM hemin (Figure 4, D and F). This effect was dose dependent 
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(Figure 4, E and G). Hx at 5 μM inhibited this increase, while equimolar HSA had no effect (Supplemen-
tal Figure 6, G and H). The dotted lines in Figure 4, B, E, and G, represents the surface expression in 
absence of  heme (0 heme in the titration curve).
RBC membranes induce complement activation in a heme-dependent manner. RBC MVs may represent a 
significant and pathological form of  heme carrier in plasma, particularly during intravascular hemolysis 
and more specifically in SCD (5). Such RBC MVs are present in our SCD mouse models (Supplemental 
Figure 1, A and B). We tested the potential capacity of  human RBC membrane-derived MVs to activate 
complement, measured by Ba release, and the inhibitory effect of  Hx. First, we compared the comple-
ment-activation capacity of  RBC MVs generated in vitro using two different methods in order to trigger 
vesiculation: a Ca2+ ionophore or mechanical stimulation (shear stress). MVs prepared with the Ca2+ 
ionophore were selected for further studies due to the higher production yield (Supplemental Figure 7A).
Stimulating ECs with these MVs induced a dose-dependent increase in both Ba and sC5b-9 release 
(Supplemental Figure 7, B and C). SCD RBC MVs (which carried about twice the heme of  control 
RBC MVs, as previously described, ref. 5) significantly increased Ba and sC5b-9 release compared with 
healthy donor (HD) levels (Figure 5, A and B). There was a linear correlation of  Ba with sC5b-9 release 
(Figure 5C). Hx significantly but partially decreased complement activation for SCD and HD RBC 
MVs (Figure 5, D and E, and Supplemental Figure 7D). The MVs expose phosphatidylserine, which is 
a potent (16) complement activator, explaining thus the fraction of  heme-independent Ba and sC5b-9 
Figure 3. Heme and not Hb induced com-
plement activation in serum and on EC 
surface, which was controlled by Hx. (A) 
NHS was incubated with 50 μM hemin, 
12.5 μM Hb (1 molecule of Hb contains 4 
heme molecules) diluted in TBS. After 
a 30-minute incubation time at 37°C, 
the level of released Ba was measured 
by ELISA. *P < 0.005, Kruskal-Wallis 
with Dunn’s test for multiple pairwise 
comparisons. (B) HUVECs were treated 
with increasing concentrations of hemin 
or diluted in FCS-free culture medium 
(M199) for 30 minutes at 37°C. After 
removing the supernatant, HUVECs were 
exposed to NHS (33% final concentra-
tion diluted in the same medium) for 30 
minutes at 37°C. Cells were detached and 
stained for C3 deposition by flow cytom-
etry. (C–F) HUVECs were treated with 
increased concentrations of hemin with 
or without 5 μM of Hx for 30 minutes at 
37°C. After removing the supernatant, 
HUVECs were exposed to NHS (33% final 
concentration diluted in M199 FCS-
free) for 30 minutes at 37°C. Cells were 
detached and stained for C3 deposition 
(C and D) or C5b-9 formation (E and F) by 
flow cytometry. (C and E) Representative 
flow cytometry histograms. (D and F) 
Quantitative analyses. *P < 0.05, **P 
< 0.005, ***P < 0.001, ****P < 0.0001, 
2-way ANOVA with Sidak’s test for 
multiple comparisons. Values are shown 
as box plots with median and minimum/
maximum points.
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and the partial effect of  Hx. Of  note, RBC MVs from SCD patients during VOC or patients at steady 
state stimulated an equivalent release of  Ba and sC5b-9 complexes (Supplemental Figure 7, E and F).
We then tried to model RBC MVs with synthetic phospholipid multilayer vesicles (MLVs), com-
posed of  phosphatidylcholine and phosphatidylserine and artificially loaded with heme. Empty MLV 
activated complement, as illustrated by sC5b-9 release in NHS, in a Hx-insensitive fashion (Supple-
mental Figure 8A). However, heme-loaded MLVs induced even stronger sC5b-9 release in fluid phase, 
which was blocked by Hx (Supplemental Figure 8B), similarly to the results with free heme (Supple-
mental Figure 8C).
We found a significant increase of  C3 deposition on endothelial surfaces in the presence of  SCD MVs, 
compared with HD MVs (Figure 5, F and G). Hx prevented C3 deposition (Figure 5H). On endothelium, 
Figure 4. Heme induced complement-related stress 
markers on the EC surface, which can be controlled by 
Hx. HUVECs were treated with increasing concentra-
tions of hemin with or without 5 μM Hx for 30 minutes 
at 37°C. Cells were detached and stained for MCP (A and 
B), C3aR (D and E), or C5aR (F and G) expression by flow 
cytometry. *P < 0.05, **P < 0.005, ***P < 0.001, ****P 
< 0.0001, 2-way ANOVA with Sidak’s test for multiple 
comparisons. (A, D, and F) Histograms from flow cytom-
etry. (B, E, and G) Quantitative analyses. (C) HUVECs 
were treated with 50 μM heme with or without 5 μM Hx. 
Expression of P selectin (false red color) was stained 
and studied by immunofluorescence. Nuclei are stained 
with DAPI (blue). Original magnification, ×63.
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a concentration of  1,000 SCD MVs/μl had comparable effects to 6 μM free hemin. The concentration of  
heme previously reported in a similar preparation of  RBC MVs approximated 5 μM (5).
Hemolysis and heme activate complement by the alternative pathway. We confirmed here that hemin acti-
vates complement by the alternative pathway (AP) in NHS (11, 12) (Supplemental Figure 8C), since the 
sC5b-9 release in presence of  Ca2+ chelator EGTA and Mg2+ (allowing activation of  the AP only) was 
identical to that in the presence of  Ca2+ and Mg2+ in the buffer (allowing activation of  all pathways). 
Similar results were obtained for HD MVs and MLVs (Supplemental Figure 8, A, B, and D). Moreover, 
Ba, which is a specific marker of  the AP, was released after addition of  RBC MVs in sera and is sensitive 
to Hx (Figure 5, A and D).
To evaluate the contribution of  the AP in vivo, we induced hemolysis in C1q–/– mice, which are unable 
to activate the classical pathway. C3 deposits in kidneys were still present despite C1q deficiency (Supple-
mental Figure 8E).
Figure 5. Erythrocyte MPs from SCD patients activated complement in a heme-dependent, Hx-sensitive manner. (A and B) NHS was incubated with 
1,000 MV/μl RBC MVs from HDs (n = 12) or SCD patients (n = 12) diluted in TBS. After 30 minutes at 37°C, the levels of released Ba (A) and sC5b-9 (B) were 
measured by ELISA. **P < 0.005, Mann-Whitney test. (C) Linear correlation between measured Ba and sC5b-9 levels with RBC MPs from SCD (n = 12) in 
tested samples. R2 = 0.4811; P = 0.0085. (D and E) NHS was incubated with 1,000 MV/μl MVs from SCD patients (n = 12) diluted in TBS with or without 
25 μM Hx. After 30 minutes at 37°C, the levels of released Ba (D) and sC5b-9 (E) were measured by ELISA. *P < 0.05, ***P < 0.001, Wilcoxon test after a 
Shapiro-Wilk test for normality. (F and G) HUVECs were treated with 1,000 MV/μl RBC MPs from HDs (n = 4) or SCD patient (n = 7) diluted in M199 medium 
for 30 minutes at 37°C. Without removing the supernatant, HUVECs were exposed to NHS (final concentration at 33% diluted in M199 FCS-free) for 30 
minutes at 37°C. Cells were detached and stained for C3 deposition by flow cytometry. (F) Flow cytometry histograms. (G) Quantitative analyses. *P < 0.05, 
Mann-Whitney test. (H) HUVECs were treated with 1,000 MV/μl RBC MPs from 1 SCD patient with or without 5 μM Hx. As above, NHS was added and cells 
were stained for C3 deposition by flow cytometry. Values are shown as box plots with median and minimum/maximum points.
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Discussion
The results presented here helped decipher the mechanisms of  complement activation triggered by intravas-
cular hemolysis. Complement activation in kidneys is a key factor for local inflammation and vascular and 
tissue damage in a large spectrum of renal diseases (21). C3 fragment deposition within tissues represents a 
durable signal of  tissue inflammation as well as a sensitive and robust indicator of  disease activity (22). On 
the other hand, intravascular hemolysis plays a key role in the pathogenesis of  renal dysfunction in SCD (23).
We observed significant C3 deposits in human SCD nephropathy biopsies and in kidneys of  two mouse 
models of  SCD. Our study of  plasma heme and Hb levels confirmed significant levels of  intravascular hemo-
lysis and cell-free heme of  both models. A similar pattern of  C3 fragment deposition was observed in exper-
imental intravascular hemolysis (PHZ induced). Moreover, we report glomerular C5b-9 deposits in human 
and mouse SCD kidneys for the first time to our knowledge. We concluded that complement activation is 
associated with intravascular hemolysis and, more specifically, the increase in cell-free heme in plasma. In 
addition, this pathway progresses up to its terminal phase, with membrane attack complex formation in SCD.
We investigated the molecular connection between intravascular hemolysis and complement activation. 
We found that injection of  Hb or heme both induced complement deposition, and these deposits were atten-
uated by pretreatment with Hp and Hx. In our experiments, Hx prevented complement activation mediated 
by Hb. This indicated that Hb operates indirectly via liberation of  heme. In fact, the induction of  hemolysis 
rapidly activated complement and endogenous Hx levels dropped at the same time, suggesting a direct link 
Figure 6. Schematic view of different nonexclusive mechanisms leading to complement activation during hemolysis. Extracellular heme can serve as an 
enhancer of the pathological process in SCD and other hemolytic diseases. (i) Heme activates EC by its proinflammatory and prooxidant effects. (ii) Heme 
induces hydrolysis of C3 into C3(H2O) and provokes direct complement activation in the serum. (iii) C3b generated by the fluid-phase C3 convertase will 
bind to the EC membrane and will form new AP C3 convertases that can locally autoamplify and generate C3b and C5b-9 deposition. (iv) Released C3a and 
C5a can bind to C3aR and C5aR to mediate proinflammatory processes. In the context of SCD, sickle RBCs will generate more heme-positive MVs. They 
carry heme, which will activate complement in serum and also on the EC surface. We hypothesize that this complement activation will contribute to the 
vascular injury and tissue damage in SCD. Hx was able to block, partially or completely, the hemolysis-induced complement activation in vitro and in vivo.
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between the increase in cell-free heme and Hx consumption. From this group of  data, we concluded that 
intravascular hemolysis triggered complement activation, in a process mediated by the release of  Hb by RBCs, 
which was dependent on the activation of  cell- and globin-free heme, likely released during spontaneous Hb 
oxidation in plasma. Deposits persisted despite the Hx normalization and HO-1 expression at 24 hours, due 
to the covalent attachment of  C3b/iC3b to the cell surface. Existing literature includes proteomic analyses of  
kidneys from old blood-transfused hemolytic mice and revealed increased presence of  complement proteins 
of  the AP (Factors C3, B, and D); those were attenuated by Hp administration (24). Here, complement acti-
vation in response to intravascular hemolysis progressed through the AP, despite suspected effects of  heme on 
immunoglobulins, or the potential activation of  the classical pathway (2, 20, 25–27). This corroborates previ-
ous clinical reports of  increased AP activation marker Bb and sC5b-9 complexes in SCD patient sera (13–15).
We simulated the secondary mediators released by RBCs during intravascular hemolysis. We studied 
complement activation in vitro in response to heme, Hb, and RBC-derived MVs. Once released in the cir-
culation, heme is likely to bind promptly to one of  its multiple proteic or lipidic partners, due to its highly 
hydrophobic nature. RBC-derived membrane MVs represent a significant form of  heme carrier in plasma 
during intravascular hemolysis (5), and their levels increase about 3-fold during VOC in SCD (28, 29). 
RBC-derived MVs contribute to chronic inflammation in SCD as well as transfusion-related complications 
(27, 30). RBC-derived MVs are sufficient to trigger VOCs in SAD mouse kidneys, in a heme-dependent 
and Hx-inhibited process (5, 7). Here, RBC-derived MVs from SCD patients activated the alternative and 
terminal complement pathways. Artificial heme-loaded MLVs also triggered complement activation sub-
stantially, compared with MLVs alone, confirming that the MV pathway leading to complement activation 
is partially mediated by heme. The established presence of  RBC-derived MVs in SCD patients, SAD and 
HbSS mice, as well as in PHZ-injected WT mice, combined with our observation of  a direct, heme-depen-
dent complement activation by human RBC MVs, suggests that RBC-derived MVs are a pathologically 
relevant form of  heme carrier involved in complement activation.
In cultured ECs, C3 and C5b-9 deposition occurred upon brief  exposure to heme but not Hb and could 
be prevented by the use of  Hx. These deposits could be explained by a rapid cell surface expression of  P 
selectin. P selectin is known to recruit C3b (31, 32) and represents an interesting therapeutic target as a 
mediator of  blood cell adhesion to vessel walls and VOC in SCD (33, 34). When exposed to heme, ECs 
partly lost C3b-regulating MCP and increased their expression of  C3aR and C5aR. This supports the C3aR 
upregulation reported in transfusion-induced hemolysis (35). Hence, hemolysis, and heme in particular, 
unlike Hb alone, may enhance the responsiveness of  ECs to complement-mediated inflammation. High lev-
els of  soluble C3a and C5a can then bind to C3aR and C5aR to mediate pro-inflammatory processes. We 
have previously shown that heme induces hydrolysis of  C3 into C3(H2O) and provokes direct complement 
activation in sera (2, 9–12). C3b generated by the fluid-phase C3 convertase will bind to EC membranes and 
form new C3 convertases of  the AP, which can autoamplify locally and increase C3b and C5b-9 deposition.
Together, our data established that intravascular hemolysis induces the activation of  the complement 
AP via RBC degradation products, and EC sensitization to complement, in transgenic mouse models with 
SCD and in SCD patient biopsies (Figure 6).
Our data points at potential avenues to target inflammatory processes during intravascular hemolysis. 
One such possibility is indirect complement inhibition by heme-scavenging approaches. The experimen-
tal injection of  Hx prior to PHZ, Hb, or heme administration clearly attenuated complement deposition, 
demonstrating the causal role of  cell-free, globin-free heme. In vitro experiments showed that Hx, and HSA 
at much higher concentrations, protected ECs from heme-mediated stress and subsequent complement acti-
vation in vitro. HSA is present at higher levels in plasma compared with Hx and can boost heme scavenging 
and protection against complement activation. Nevertheless, Hx, but not HSA, was effective at preventing 
tissue injury and inflammation in mouse models of  hemolysis (5, 36–39). Previous reports have also shown 
that hepatic overexpression of  Hx inhibits inflammation and vascular stasis in murine SCD (40), while 
Hx–/– mice develop a severe renal damage after experimental hemolysis. This points to Hx as a guardian of  
kidney function during intravascular hemolysis (41). Hx could be also useful in cases of  cardiac dysfunction 
subsequent to hemolysis. Indeed, in a model of  repetitive injections of  PHZ, oxidative stress in the heart was 
counteracted with preventive injections of  Hx (39). The recent discovery of  a specific antibody against heme, 
2H10, will provide further information about the contribution of  heme to the pathological consequences of  
hemolytic diseases (42). Benefits of  Hx reflect deleterious effects of  heme. Therapeutic Hx administration to 
alleviate heme-induced inflammation is under intense scrutiny, particularly in SCD (5, 36–39). However, Hx 
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.96910
R E S E A R C H  A R T I C L E
administration remained insufficient to prevent inflammation and renal injury in an old blood transfusion 
model of  hemolysis (5, 36–39) as well as in our pharmacological model of  hemolysis (43). Acute intravas-
cular hemolysis may generate other RBC-derived products (Hb, MVs, etc.) in quantities sufficient to sustain 
tissue injury independently from heme. Indeed, hemolysis and MV formation during blood storage and in 
patients receiving a transfusion of  aged RBCs contribute to decreased NO bioavailability and vascular dys-
function in a Hb-dependent manner (44). Conversely, Hp administration decreased renal injury significantly 
in the transfusion model (5, 36–39).
Taken together, our results and the data from the literature point toward a complex role of  RBC deg-
radation products in renal damage. It is well established that SCD nephropathy is a multifactorial pro-
cess, related to NO scavenging by Hb, ROS generation, and heme-mediated injury (44–48). Here, we add 
heme-mediated complement activation as additional mechanism, potentially contributing to SCD kidney 
injury. Evidence for a pathogenic role of  complement activation in hemolysis-induced renal manifestations 
comes from the observed attenuation of  the expression of  NGAL and Kim-1 in complement C3-deficient 
mice. Moreover, targeting C5 with a blocking antibody was shown to inhibit VOCs in transgenic mice with 
SCD (49), while inhibiting C3 with compstatin CP40 has been investigated in vitro in a model of  malaria 
(50, 51). However, CP40 is still unavailable for clinical use. Complement inhibition downstream of  C3 is 
now possible in the clinic, using the monoclonal, C5-blocking antibody eculizumab, which abrogates ter-
minal pathway activation. Cases supporting the efficacy of  eculizumab against delayed transfusion reaction 
and hemolysis in SCD are emerging (52), showing the importance of  complement in the disease. Although 
we detected complement deposits in SCD nephropathy biopsies and mouse models of  SCD, our results 
do not provide direct proof  that complement is implicated in the renal injury. Nevertheless, our data urge 
for further studies in order to determine how much complement activation contributes to the pathological 
processes in chronic hemolytic diseases, including SCD nephropathy.
In summary, our study demonstrates alternative and terminal complement pathway activation during 
intravascular hemolysis and in SCD. It also suggests that heme-scavenging strategies, such as Hx supple-
mentation, could indirectly help target complement activation (Figure 6).
Methods
Reagents
The Fe3+ form of  heme (hemin [ferriprotoporphyrin IX], designated as heme (Frontier Scientific Inc. or 
MilliporeSigma) was dissolved to 20 mM in 50 mM NaOH and 145 mM NaCl and further diluted in an 
appropriate vehicle just before use.
Stock solution of  25 mg/ml PHZ (MilliporeSigma) was prepared in PBS immediately before use. Plas-
ma-purified Hx, Hp, and HSA were provided by CSL Behring. Complement ELISA kits MicroView Ba 
and sC5b-9 were from Quidel. MVs were obtained from SCD patients or HD RBCs after vesiculation with 
calcium ionophore A23187 or mechanical vesiculation as previously described (7).
Patients
Patients. Kidney biopsies and corresponding clinical data from 13 SCD patients were retrieved from the 
archives of  the Necker-Enfants Malades Hospital, Paris, France (n = 10), and the Pathology Institute of  the 
CHRU Lille, Lille, France (n = 3), to constitute a cohort of  SCD nephropathy (Table 1) A normal protocol 
kidney allograft biopsy, performed at 3 months, was used as a negative control. A biopsy of  a patient with 
acute humoral rejection and another from a patient with lupus nephritis were used as positive controls for 
the staining.
Classification of  SCD patients. Kidney biopsy of  13 SCD patients is detailed in Table 1. In 6 cases, kidney 
biopsies were performed because of  chronic renal failure, and in the remaining 7 cases, kidney biopsies 
were performed because of  proteinuria. The grading scale used was as follows: -, no lesion; +, rare or few 
lesions; ++, moderate lesions; and +++, severe lesions.
Staining for complement in patient kidney biopsies. Routine staining protocol for C3 (polyclonal rabbit anti-
C3c Human Complement/FITC, Dako, F0201) was applied for the patients with missing archived imag-
es. For the 3 patients from CHRU Lille, C9 staining was also available (rabbit anti-human C9, Abcam, 
ab71330) using the Ventana XT autostainer (Ventana Medical Systems, BenchMark XT). Whole slides 
were scanned and analyzed by an Axio Scan (Zeiss) or Nanozoomer (Hamamatsu).
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Animal experimentation
Mouse treatment. C57BL/6 mice were from Charles River Laboratories, and C1q–/– and C3–/– mice (C57BL/6 
background) were from an in-house colony, which was a gift from Marina Botto (Imperial College London, 
London, United Kingdom) and Sebastien Lacroix-Desmazes (Cordeliers Research Center, Paris, France). 
Eight-week-old female C57BL/6 WT mice were injected i.p. with 200 μl PBS (Gibco) or PHZ (900 μmol/
kg, corresponding to 0.125 mg/g body weight), and the mice were sacrificed at 6 or 24 hours. WT C1q–/– 
and C3–/– mice were injected with the same dose of  PHZ and sacrificed at 24 hours. Alternatively, PBS, 40 
μmol/kg freshly prepared heme (corresponding to 26 μg/g body weight, ref. 6), or 12.5 μmol/kg freshly 
prepared human Hb (corresponding to 800 μg/g body weight) was injected, and the mice were sacrificed at 
24 hours. To test the efficacy of  Hx, mice were pretreated with i.p. injection of  0.491 μmol/kg human plas-
ma-derived Hx (corresponding to 28 μg/g body weight, ref. 36) diluted in PBS 1 hour before i.p. injection 
of  PBS or freshly prepared heme, Hb, or PHZ, as above. The efficacy of  Hp was tested by pretreatment of  
the mice with 1 μmol/kg human plasma-derived Hp (corresponding to 250 μg/g body weight) diluted in 
PBS 1 hour before i.p. injection of  PBS or PHZ. Concentrations and route of  administration were chosen 
as described previously (6, 36, 39). Blood was collected from the submandibular vein 3 days before the first 
injection (baseline), at 6 hours, and before endpoint (day 1).
SAD mice. SAD mice carry a human Hb β chain transgene with 3 mutations (bS b6Val, bS-Antilles, 
b23Ile, and D-Punjab b121Glu) on a C57BL/6J background; they are a well-characterized model of  SCD 
and SCD-associated renal injury (17). Frozen kidneys from 6-month-old SAD mice were used for this study.
HbSS mice (Townes). HbSS mice express human α-globin gene on a C57BL/6 background; they are a 
well-described model of  SCD (53). Frozen kidneys from 3-month-old HbAA and HbSS mice were used 
for this study.
Immunofluorescence of  mouse tissue. Five-μm-thick frozen sections of  kidneys, hearts, and spleens were 
cut with Cryostat Leica AS-LMD and fixed in acetone on ice for 10 minutes. Complement deposition was 
studied using rat anti-mouse C3 fragments (C3bi/C3b/C3c) IgG1 (Hycult Biotech, HM1065), visualized 
with goat anti-rat-AF488 (Invitrogen, A-11006) and rabbit anti-mouse C5b-9 (Abcam, ab55811), and visu-
alized with goat anti-rabbit IgG-AF488 (Invitrogen, A-11008). Double staining for C3 deposition and EC 
marker CD31 was performed using rabbit anti-mouse CD31 (Abcam, ab28364), revealed by anti-rabbit 
AF555 (Invitrogen, A-21429). Stained slides were scanned by Slide Scanner Axio Scan (Zeiss) or analyzed 
by confocal microscopy (Confocal LSM710, Zeiss). Quantification of  the staining was performed using 
Visiopharm software (Visiopharm A/S) by measuring the fluorescence intensity of  the staining within the 
cortex reported on the total cortical surface.
Immunohistochemistry of  mouse tissues. Five-μm-thick frozen sections of  kidneys and hearts were cut with 
Cryostat Leica AS-LMD and fixed in acetone on ice for 10 minutes. Complement deposition was studied 
using rat anti-mouse C3 fragments (C3bi/C3b/C3c) IgG1 (Hycult Biotech, HM1065), followed by a goat 
anti-rat polyclonal IgG-HRP (R&D Systems). HO-1 expression was studied using rabbit anti-mouse HO-1 
(Abcam, Ab13243), followed by a polymer anti-rabbit (DAKO, K4003). Both stainings were revealed with 
DAB solution. Slides were scanned by Nanozoomer (Hamamatsu). Hematoxylin and eosin and Perls’ col-
oration were performed by routine procedures using sections of  paraffin-embedded kidneys. Coloration of  
slides was scanned by Slide Scanner Axio Scan (Zeiss).
mRNA level analyses. Frozen kidney sections were recovered in RLT buffer (Qiagen) + 1% β-mercap-
toethanol (Gibco) and used for mRNA extraction using Qiagen RNeasy miniKit. The quality and quantity 
of  mRNA were evaluated with the Agilent 2100 bioanalyzer using the Agilent TNA 6000 NanoKit, fol-
lowed by retrotranscription to cDNA. Gene markers of  early kidney injury, NGAL, Kim-1, and the cyto-
protective gene HO-1, relevant for hemolysis were analyzed by RTqPCR (ThermoFisher).
Quantification of  cell-free heme, Hb, and MVs in plasma. An approximation of  extracellular heme levels in 
blood was obtained by measuring absorbance at 398 nm in mouse plasma, i.e., at the peak of  Soret band 
absorbance. Straightforward absorbance in plasma can be somewhat affected by turbidity, but it is assumed 
that strong and sudden increases obtained in transgenic mice with SCD-like phenotypes, such as HbSS 
and SAD mice, will be mostly related to heme, as previously reported (5, 7). This technique will detect all 
forms of  heme, whether it is retained within Hb or bound to other plasma partners and will reflect intravas-
cular hemolysis accurately, which is further confirmed here with the PHZ-induced model. To confirm the 
occurrence of  intravascular hemolysis, we assessed the levels of  Hb in plasma using a completely different 
principle and a mouse Hemoglobin ELISA Kit (Abcam, ab157715), following the manufacturer’s protocol.
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In addition to heme and Hb, we evaluated the circulating levels of  membrane-derived extracellular MVs 
in the plasma of  our hemolysis models, with our well-established method (5, 7). Briefly, MVs present in 
plasma were labeled with fluorescent recombinant annexin A5 (labeled with FITC, Merck), analyzed by 
fluorescence-assisted cell sorting using an LSR II flow cytometer (BD Biosciences), and compared with 
size-calibrated microbeads (MegamixPlus Biocytex) and fluorospheres (Flow-Count, Beckman Coulter) to 
calibrate volume. In some experiments, plasma were depleted from MVs by ultracentrifugation (20,500 g for 
4 hours; Eppendorf  5804R). Pelleted MVs were discarded, leaving behind any material not bound to MVs.
Flow cytometry assessment of  C3b/iC3b on mouse RBCs. Blood from PBS-, PHZ-, or heme-injected mice 
was recovered 24 hours after injection and RBCs were purified. These cells were stained for C3 fragment 
deposition using rat anti-mouse C3bi/C3b/C3c IgG1 (Hycult Biotech, HM1065) and visualized with goat 
anti-rat AF488 (Invitrogen, A-11006). Alternatively, RBCs from naive mice were purified and incubated 
at 1 × 106 cells/tube for 30 minutes with 50 μM heme, followed by addition of  normal mouse serum for 
30 minutes. Cells were washed and probed for C3 fragment deposits by flow cytometry (BD LSR II) and 
further analyzed by FlowJo X.
Hx quantification. Ten μl of  plasma sample was placed into a clean Eppendorf  tube followed by the 
addition of  75 μl MeOH to precipitate the protein. The methanol was removed after centrifugation. The 
pellet was air dried and afterward resuspended in 50 mM NH4HCO3/0.16% ProteaseMAX (Promega) 
containing heavy-isoptope labeled peptides, which are specific for human Hx or endogenous Hx and 
used as internal standards. Samples were incubated at 56°C/550 rpm for 45 minutes, reduced by adding 
0.5 M DTT (56°C/550 rpm for 20 minutes), and afterward alkylated by adding 0.5 M IAA and incu-
bated for 20 minutes at room temperature protected from light. Tryptic digestion was carried out at 
37°C/550 rpm for 3 hours, and the samples were separated immediately on a C18 column (AdvanceBio 
Peptide Mapping, Agilent; 2.1 × 250 mm). The measurements were conducted using a Agilent 6550 
iFunnel QTOF mass spectrometer connected to an Agilent 1290 Infinity II HPLC instrument.
Data were analyzed by calculating the peak area of  the analyte and the internal standard using 
Agilent MassHunter Quant software. A standard curve was created by Agilent MassHunter Quant, 
with which the average ratio of  the analyte response to the internal standard response against concen-
tration was plotted.
Complement activation and complement receptors on ECs
Flow cytometry. Primary HUVECs were cultured on 24-well plates as previously described (12, 54) and 
exposed to heme or RBC MVs at the indicated doses for 30 minutes at 37°C in serum-free M199 cell 
culture medium (Gibco) in presence or absence of  Hx or HSA. For evaluation of  complement activa-
tion, HUVECs were washed and further exposed to NHS diluted to 33% in M199 medium or serum was 
added to final dilution of  33% to the wells, already containing heme with and without Hx for 30 minutes 
at 37°C. HUVECs were used for experiments until passage 4. Cells were washed, detached, labeled, and 
fixed in 0.5% formaldehyde. Cells were analyzed by flow cytometry (BD LSR II) and further analyzed 
by FlowJo X. In addition to the corresponding isotype controls, the following antibodies were used for 
staining: anti-human MCP-RPE (Bio-Rad, MCA2113PE), anti-human C3aR-PE (BioLegend, 345804), 
and anti-human C5aR-APC (BioLegend, 344310). After incubation with serum, staining was performed 
with anti-C3c mouse monoclonal IgG1 antibody (Quidel, A205) or with anti-C5b-9 mouse monoclonal 
IgG1 (provided by Paul Morgan, Cardiff  University, Cardiff, United Kingdom) or an isotype control 
and revealed by anti-mouse-IgG1-PE secondary antibody (Beckman Coulter, IM0551).
Immunofluorescence. HUVECs were cultured on slides on 24-well plates. Cells were incubated for 5 min-
utes in presence of  50 μM of  heme, with or without 5 μM of  Hx. Cells were fixed in 4% paraformaldehyde 
after staining with anti-human P selectin primary antibody (Bio-Rad, MCA796) or an isotype control and 
revealed with AF-488 secondary antibody (Invitrogen, A21204) and DAPI (to stain nuclei). Staining was 
analyzed by an Axiovert 200 microscope (Zeiss).
Complement activation in serum
MVs, generated from HD or SCD patient RBCs, as well as artificial MLVs loaded or not with heme were 
incubated with buffer, Hx, or HSA for 10 minutes, followed by 33% NHS over 30 minutes at 37°C. MVs 
were diluted at a final concentration of  1,000 MV/μl, 2,500 MV/μl, or 5,000 MV/μl in TBS with 4 mM 
CaCl2 and 4 mM MgCl2, allowing activation of  the 3 complement pathways. Otherwise, MVs were diluted 
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in TBS with 10 mM EGTA and 4 mM MgCl2, thus allowing activation of  the AP only. The contribution of  
the AP was determined by the difference in the signal between the two conditions. Ba and sC5b-9 levels in 
the serum were evaluated according to the ELISA kit instructions (Quidel). EDTA was used as a negative 
control to block complement activation.
Statistics
Results were analyzed using a statistical software package (GraphPad Prism 5) using the Mann-Whit-
ney test, Kruskal-Wallis with Dunn’s test for multiple pairwise comparisons, 2-way ANOVA with 
Sidak’s test for multiple comparisons or Tukey’s test for multiple comparisons, or Wilcoxon test after a 
Shapiro-Wilk test for normality. P values inferior to 0.05 were considered significant.
Study approval
All animal experiments were conducted with the approval of  and in accordance with the recommenda-
tions for the care and use of  laboratory animals provided by Charles Darwin ethical committee (Par-
is, France) and with the approval of  the French Ministry of  Agriculture, Paris, France (APAFIS 3764-
201601121739330v3). Patients provided written informed consent for the biopsies, the use of  clinical 
data, and the secondary use of  histological material for research. This study was performed in accordance 
with the Declaration of  Helsinki. The samples from the HEMIR collection were used for this study. The 
HEMIR collection was declared to the French Research Ministry (Paris) with approval no. DC.2011-1450.
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